TY - JOUR
T1 - New Noonan syndrome model mice with RIT1 mutation exhibit cardiac hypertrophy and susceptibility to β-adrenergic stimulation-induced cardiac fibrosis
AU - Takahara, Shingo
AU - Inoue, Shin ichi
AU - Miyagawa-Tomita, Sachiko
AU - Matsuura, Katsuhisa
AU - Nakashima, Yasumi
AU - Niihori, Tetsuya
AU - Matsubara, Yoichi
AU - Saiki, Yoshikatsu
AU - Aoki, Yoko
PY - 2019/4
Y1 - 2019/4
N2 - Background: Noonan syndrome (NS)is a genetic disorder characterized by short stature, a distinctive facial appearance, and heart defects. We recently discovered a novel NS gene, RIT1, which is a member of the RAS subfamily of small GTPases. NS patients with RIT1 mutations have a high incidence of hypertrophic cardiomyopathy and edematous phenotype, but the specific role of RIT1 remains unclear. Methods: To investigate how germline RIT1 mutations cause NS, we generated knock-in mice that carried a NS-associated Rit1 A57G mutation (Rit1 A57G/+ ). We investigated the phenotypes of Rit1 A57G/+ mice in fetal and adult stages as well as the effects of isoproterenol on cardiac function in Rit1 A57G/+ mice. Findings: Rit1 A57G/+ embryos exhibited decreased viability, edema, subcutaneous hemorrhage and AKT activation. Surviving Rit1 A57G/+ mice had a short stature, craniofacial abnormalities and splenomegaly. Cardiac hypertrophy and cardiac fibrosis with increased expression of S100A4, vimentin and periostin were observed in Rit1 A57G/+ mice compared to Rit1 +/+ mice. Upon isoproterenol stimulation, cardiac fibrosis was drastically increased in Rit1 A57G/+ mice. Phosphorylated (at Thr308)AKT levels were also elevated in isoproterenol-treated Rit1 A57G/+ hearts. Interpretation: The A57G mutation in Rit1 causes cardiac hypertrophy, fibrosis and other NS-associated features. Biochemical analysis indicates that the AKT signaling pathway might be related to downstream signaling in the RIT1 A57G mutant at a developmental stage and under β-adrenergic stimulation in the heart. Fund: The Grants-in-Aid were provided by the Practical Research Project for Rare/Intractable Diseases from the Japan Agency for Medical Research and Development, the Japan Society for the Promotion of Science KAKENHI Grant.
AB - Background: Noonan syndrome (NS)is a genetic disorder characterized by short stature, a distinctive facial appearance, and heart defects. We recently discovered a novel NS gene, RIT1, which is a member of the RAS subfamily of small GTPases. NS patients with RIT1 mutations have a high incidence of hypertrophic cardiomyopathy and edematous phenotype, but the specific role of RIT1 remains unclear. Methods: To investigate how germline RIT1 mutations cause NS, we generated knock-in mice that carried a NS-associated Rit1 A57G mutation (Rit1 A57G/+ ). We investigated the phenotypes of Rit1 A57G/+ mice in fetal and adult stages as well as the effects of isoproterenol on cardiac function in Rit1 A57G/+ mice. Findings: Rit1 A57G/+ embryos exhibited decreased viability, edema, subcutaneous hemorrhage and AKT activation. Surviving Rit1 A57G/+ mice had a short stature, craniofacial abnormalities and splenomegaly. Cardiac hypertrophy and cardiac fibrosis with increased expression of S100A4, vimentin and periostin were observed in Rit1 A57G/+ mice compared to Rit1 +/+ mice. Upon isoproterenol stimulation, cardiac fibrosis was drastically increased in Rit1 A57G/+ mice. Phosphorylated (at Thr308)AKT levels were also elevated in isoproterenol-treated Rit1 A57G/+ hearts. Interpretation: The A57G mutation in Rit1 causes cardiac hypertrophy, fibrosis and other NS-associated features. Biochemical analysis indicates that the AKT signaling pathway might be related to downstream signaling in the RIT1 A57G mutant at a developmental stage and under β-adrenergic stimulation in the heart. Fund: The Grants-in-Aid were provided by the Practical Research Project for Rare/Intractable Diseases from the Japan Agency for Medical Research and Development, the Japan Society for the Promotion of Science KAKENHI Grant.
KW - AKT
KW - Cardiac fibrosis
KW - Cardiac hypertrophy
KW - Noonan syndrome
KW - RIT1
UR - http://www.scopus.com/inward/record.url?scp=85063000604&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063000604&partnerID=8YFLogxK
U2 - 10.1016/j.ebiom.2019.03.014
DO - 10.1016/j.ebiom.2019.03.014
M3 - Article
C2 - 30898653
AN - SCOPUS:85063000604
VL - 42
SP - 43
EP - 53
JO - EBioMedicine
JF - EBioMedicine
SN - 2352-3964
ER -